My Passport
News and Commentary education Live Coronavirus Dashboard
S&P 500 ETF
0.00%
NASDAQ ETF
0.00%
Dow Jones ETF
0.00%


Google, Anthropic Deal In Jeopardy As US Just...
Gary Gensler To Step Down As SEC Chair On Tru...
Comcast's Spin-Off to Boost Broadband and Str...
MicroStrategy Surges 674% In 2024: 5 ETFs Tha...
Alibaba Reshapes E-Commerce Operations, Names...
Target Posts Q3 Earnings Miss: Analysts Slash...
Natural Gas Prices Spike To Over 1-Year Highs...
Nvidia Delivered 'Jaw Dropping' Q3 Earnings,...
The Rise of the Solo General Partner Investor

While modern day venture capital originated in the 1940s, the very first iteration of venture capital (VC) investments--where a general partner (GP) investments capital on behalf of a limited partner (LP)--dates all the way back to the early 1600s with the founding of East India...

  • How are Higher Rates Impacting the Housi...
  • Quantitative Tightening: How the Fed Co...
  • Should Investors Worry About Inflation?
  • How Semiconductors are Made and Why its...
  • What Are NFTs?
    • Inflation: What is it and How to Protect From...
    Short Squeezes Could Lead to Market Dislocati...
    How Google and Facebook Antitrust Lawsuits Co...
    Vaccine News Triggers Growth to Value Rotatio...
    Energy
    Materials
    Industrial
    Finance
    Consumer D...
    Consumer S...
    Informatio...
    Telecommun...
    Health Car...
    Utilities
    Oil
    Gold
    ETFs IPOs Ratings
     
    S&P 500 ETF
    0.00%
    NASDAQ ETF
    0.00%
    Dow Jones ETF
    0.00%
    Search
    News and Commentary
    Education
    Market
    ETFs
    IPOs
    Ratings
    Newsfeed
    My passport
    Login
    Sign up

    SAGE THERAPEUTICS INC (NASDAQ: SAGE)

    Overview
    current price
    $4.85
    $4.85
    change
    0.00 | 0.00%
    0.00 | 0.00%
    Yesterday's Close
    4.85
    open
    0.00
    volume
    0.00 M
    30d. avg volume.
    0.79 M
    1 day
    0.00 - 0.00
    52 weeks
    4.62 - 28.26
    p/e
    0.00
    beta
    0.9208
    market cap
    0.30 B
    dividend yield
    0.00%
    Industry
    -
    SAGE by TradingView
    News and Commentary
    New Drug to Treat Schizophrenia Approved by FDA The U.S. Food and Drug Administration (FDA) has approved Caplyta (lumateperone), a drug developed by Intra-Celullar Therapies Inc.
    Neuro Drug Stocks Rise Following Intra-CellularTherapies' Drug Approval One indisputable trend about the modern world is that people are living longer. In 1950, the average lifespan for an American was 68 years old. Today, it's 78. One result of a lo...
    StockTwits
    StockTwits
    Most Shared
    SolarEdge Q3 Results Miss Expectations; Analysts Warn Of Cash Flow Challenges And Need For Cost Cuts
    US Economy Grows Less Than Expected In Q3, Yet Private Employment Soars By 233,000 In October
    Netflix Crash Hits Jake Paul-Mike Tyson Fight: Can Streaming Platform Handle Christmas Day NFL Action?
    Most Popular
    Meta, Amazon, Microsoft Partner On Defense AI Initiative
    Ford CEO Jim Farley Says He Tries To Drive All Vehicles From Competition After Expressing Adoration For Xiaomi SU7: 'Try Me,' Says Tesla Cybertruck
    Palantir Overtakes Lockheed Martin In Market Cap, How Does The 'Messi Of AI' Stack Up Against The Traditional Defense Player
    popular tags
    Earnings
    Coronavirus
    Apple
    Amazon
    Coronavirus Impact
    Covid-19
    Covid19
    Google
    Tesla
    mobile iOS Android
    social Facebook Twitter Youtube Linkedin Rss Google News
    Passport to Wall Street About Us Contact Advertise Privacy Policy Terms of Service
    Sign Up
    © 2024 Passport to Wall Street
    Quotes are at least 20 minutes delayed

    Join now and unlock premium features

    Already Have An Account?